This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Publicado 22 sept 2026 15:46 UTC |

Traducción no disponible. Inténtalo de nuevo.

Lo que informa la fuente

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

No se identificó un activo específico en este informe; explora pares USDT de referencia en vivo.